Chardan Capital Forecasts Immunic FY2025 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Immunic in a note issued to investors on Monday, September 29th. Chardan Capital analyst R. Li expects that the company will earn ($0.65) per share for the year. Chardan Capital has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share.

Several other research firms have also recently issued reports on IMUX. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Immunic in a report on Friday, September 26th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Immunic in a report on Thursday, September 25th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $9.50.

Immunic Price Performance

IMUX opened at $0.96 on Wednesday. The company has a market capitalization of $94.70 million, a price-to-earnings ratio of -1.02 and a beta of 1.56. Immunic has a 1-year low of $0.56 and a 1-year high of $1.73. The business has a 50 day moving average price of $0.89 and a two-hundred day moving average price of $0.92.

Immunic (NASDAQ:IMUX) last released its earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02).

Institutional Investors Weigh In On Immunic

A number of institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its holdings in Immunic by 279.3% during the first quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock valued at $226,000 after purchasing an additional 152,726 shares in the last quarter. Millennium Management LLC raised its position in Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock worth $580,000 after purchasing an additional 479,846 shares during the last quarter. 683 Capital Management LLC raised its position in shares of Immunic by 28.6% during the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock valued at $981,000 after acquiring an additional 200,000 shares during the last quarter. Aberdeen Group plc bought a new stake in shares of Immunic during the 1st quarter valued at $1,155,000. Finally, Focus Partners Wealth raised its position in shares of Immunic by 19.1% during the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock valued at $2,816,000 after acquiring an additional 415,104 shares during the last quarter. 51.82% of the stock is owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.